ArticleFrontiers in immunology2026

Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1).

Evelyn L Beas-Lozano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.